# Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

> **NCT00030186** · PHASE2 · COMPLETED · sponsor: **Cephalon** · enrollment: 37 (actual)

## Conditions studied

- Leukemia, Myeloid

## Interventions

- **DRUG:** CEP-701 60mg
- **DRUG:** Cep-701 80mg
- **DRUG:** Cep-701 40mg

## Key facts

- **NCT ID:** NCT00030186
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2003-02
- **Final completion:** 2003-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2012-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030186, "Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00030186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*